Level 3ESMO Congress 2026
Junseok W Hur · Abstract 2446P · Poster
AbstractPosterPoster PDF. An ASCO or ESMO member login may be required.
Level 3ESMO Congress 2026
Maria Honholt Jorgensen · Abstract 4273P · Poster
AbstractPosterPoster PDF. An ASCO or ESMO member login may be required.
Level 2ESMO Gastrointestinal Cancers Congress 2026
Kozo Kataoka · Abstract 8O · Proffered Paper (oral) · GALAXY
AbstractSlidesWebcastSlides + webcast. An ASCO or ESMO member login may be required.
Level 1negativeASCO Annual Meeting 2025
Tie, Jeanne · Abstract 3503 · DYNAMIC-III · 961 eligible randomized; 259 (27%) ctDNA-positive (this analysis). 115/129 in the ctDNA-informed arm received escalation (65 FOLFOXIRI).
tumor-informed (commercial name not stated in this abstract)
2-year RFS with ctDNA-informed escalation was 52% vs 61% with standard of care (HR 1.11, 90% CI 0.83-1.48; P=0.6). 3-year RFS was similar for FOLFOXIRI vs FOLFOX/CAPOX (47% vs 51%; HR 1.09, P=0.7). Recurrence risk increased with ctDNA burden (3-year RFS 78%, 63%, 36%, and 22% across MTM/mL quartiles; P<0.01). Escalation, including to FOLFOXIRI, did not improve RFS.
AbstractFull paper
Level 2prognosticASCO Gastrointestinal Cancers Symposium 2025
Shah, Purvi K. · Abstract 15 · BESPOKE CRC · 1,001 in the sub-cohort; 625 (62.4%) received ACT; MRD-window results in 420 stage II and 505 stage III
Signatera (tumor-informed)
MRD-window ctDNA positivity was 8.1% (34/420) in stage II and 24.9% (126/505) in stage III, with DFS HR 10.4 and 10.1, respectively (both P<0.0001). Combined 24-month DFS was 91.7% if MRD-negative vs 41.4% if MRD-positive. During surveillance, conversion to ctDNA-positive was associated with markedly worse DFS in both observation and ACT-treated patients (stage II observation HR 34.9; stage III ACT HR 54.6).
Abstract
Level 1negativeASCO Gastrointestinal Cancers Symposium 2025
Bando, Hideaki · Abstract LBA22 · LBA · ALTAIR (CIRCULATE-Japan) · 243 randomized (122 FTD/TPI, 121 placebo); 96.3% had received standard-of-care postoperative therapy
Signatera (Natera), personalized tumor-informed
Median DFS was 9.30 vs 5.55 months (HR 0.79, 95% CI 0.60-1.05; P=0.107); the primary endpoint was not met. The abstract reports a more pronounced benefit in resected oligometastatic stage IV disease and a trend toward greater DFS benefit at higher baseline MTM/mL. Grade >=3 adverse events occurred in 73.0% vs 3.3%. OS data were immature (24 events).
AbstractFull paper
Level 1mixedESMO Congress 2025
Tie, J. · Abstract LBA9 · LBA · DYNAMIC-III · 702 ctDNA-negative of 968 evaluable (72.5%); 353 ctDNA-guided, 349 standard; median follow-up 45 months
tumor-informed (testing 5-6 weeks post-surgery; commercial name not stated in the abstract)
Protocol de-escalation occurred in 90.4%. Oxaliplatin-based chemotherapy use fell (34.8% vs 88.6%, P<0.001), as did grade 3+ adverse events of special interest (6.2% vs 10.6%, P=0.037) and treatment-related hospitalization (8.5% vs 13.2%, P=0.048). Non-inferiority of 3-year RFS was not confirmed (85.3% vs 88.1%; difference -2.8%; 97.5% lower CI -8.0%; NI margin 7.5%). A pre-planned subgroup of clinically low-risk T1-3N1 tumors had difference -2.2% (97.5% lower CI -7.2%), within the NI margin.
AbstractFull paperSlidesWebcastSlides + webcast. An ASCO or ESMO member login may be required.
Level 1mixedESMO Congress 2025
Marsoni, S. · Abstract 723O · oral · PEGASUS · 135 patients (100 liquid-biopsy-negative, 35 positive); median follow-up 33.5 months
Guardant Reveal (v L1.2)
Among patients with two consecutive post-surgical negative tests, 12 relapses occurred, for a 2-year no-evidence-of-disease rate of 88% (90% CI 81-93). The predefined feasibility threshold (fewer than 14 relapses among 134 negative patients to exclude 85% in favor of 92%) was not met, though the point estimate exceeded 85%. In the 35 positive patients, 13 (37%) relapsed; 2-year time-to-relapse was 87.6% vs 61.5% (HR 3.22, P=0.0013).
AbstractSlidesWebcastSlides + webcast. An ASCO or ESMO member login may be required.
Level 1positiveESMO Gastrointestinal Cancers Congress 2025
Peng, J. · Abstract LBA1 · LBA · FIND · 728 randomized (363 ctDNA-guided, 365 standard); interim, median follow-up 12 months
single-tube methylation-specific quantitative PCR (mqMSP) targeting 10 methylation markers (stated detection to 0.01% allelic fraction)
Cumulative recurrence rates did not differ (P=0.671 ITT). ctDNA-guided surveillance increased the proportion of recurrent patients who received curative-intent therapy (50.0% vs 22.6%; relative risk 2.214, 95% CI 1.060-4.780; P=0.034), the trial's primary endpoint. This is an interim analysis.
Abstract
Level 1positiveASCO Annual Meeting 2024
Tie, Jeanne · Abstract 108 · DYNAMIC · same randomized cohort; median follow-up 59.6 months
tumor-informed Safe-SeqS (as in the primary DYNAMIC report)
5-year RFS was 88% vs 87% (difference 1.1%, 95% CI -5.8% to 8.0%). 5-year OS was 93.8% vs 93.3% (HR 1.05, 95% CI 0.47-2.37; P=0.887). In treated ctDNA-positive patients, end-of-treatment clearance occurred in 35/40 (87.5%); 5-year RFS was 85.2% with clearance vs 20.0% with persistence (HR 15.4, P<0.001). Higher post-surgery mutant tumor molecules (>=0.38 MTM/mL) were associated with lower clearance and worse RFS.
Abstract
Level 1mixedASCO Gastrointestinal Cancers Symposium 2024
Tie, Jeanne · Abstract 12 · DYNAMIC-Rectal · 230 eligible (155 ctDNA-guided, 75 standard); recruitment stopped early because of COVID-19 and uptake of total neoadjuvant therapy
tumor-informed (same program as DYNAMIC; commercial name not re-stated in the extracted results)
In the ctDNA-guided arm, 42/150 (28%) with successful testing were ctDNA-positive. Adjuvant chemotherapy was used in 46% vs 77% (P<0.001). 3-year RFS was 76% vs 82% (difference 6%, 95% CI -6% to 17%). The abstract states the sample size precludes conclusions about non-inferiority. Recurrence in untreated ctDNA-negative patients was often lung-only (12/15, 80%).
Abstract
Level 2prognosticASCO Gastrointestinal Cancers Symposium 2024
Kasi, Pashtoon Murtaza · Abstract 9 · BESPOKE CRC · 154 stage II and 196 stage III in this interim subset; MRD results in 295; median follow-up 24.8 months
Signatera (tumor-informed)
MRD positivity was 15.6% (46/295; 6.9% stage II, 22.4% stage III) and was associated with inferior DFS (HR 20.8, 95% CI 10.0-43.4). Within the MRD-positive group, patients who received ACT had longer DFS than those observed (median 18.7 vs 6.7 months; HR 3.9, P=0.01). No ACT benefit was observed in MRD-negative patients (HR 1.1, P=0.89). Treatment was not randomized.
Abstract
Level 2prognosticASCO Gastrointestinal Cancers Symposium 2024
Yukami, Hiroki · Abstract 6 · GALAXY (CIRCULATE-Japan) · 2,518 analyzed of 3,034 enrolled; MRD-window results in 2,093 (309 [14.8%] positive)
Signatera (tumor-informed)
MRD-positive patients had inferior DFS (HR 15.75, 95% CI 12.59-19.68, P<0.0001). Those who remained positive 3 months after MRD detection were more than 5 times as likely to recur as those with clearance (HR 5.4, P<0.0001). Of 181 MRD-positive patients who received adjuvant therapy, 72.9% had clearance; 54% of those with later samples had sustained clearance, which was associated with far better outcomes than transient clearance (HR 32.57). A 50% or greater drop in MTM/mL at 6 months among treated MRD-positive patients was associated with better DFS (HR 2.39, P=0.004).
AbstractFull paper
Level 1negativeASCO Gastrointestinal Cancers Symposium 2024
Morris, Van K. · Abstract 5 · NRG-GI005 (COBRA) · 635 randomized (318 observation, 317 ctDNA-directed); phase II clearance analysis used the first 16 patients with baseline ctDNA detected
Guardant LUNAR (mutations plus colon cancer-specific methylation)
Clearance of ctDNA at 6 months was observed in 3/7 (43%) in the observation arm and 1/9 (11%) in the chemotherapy arm (P=0.98). The phase II endpoint was not met; enrollment was halted under prespecified stopping rules based on the original assay. No improvement in clearance was seen after 6 months of chemotherapy in ctDNA-detected resected stage IIA colon cancer. The abstract notes future integral-biomarker trials must account for assay specificity in this population.
Abstract
Level 2ESMO Congress 2024
Jun Nagata · Abstract 553P · Poster · CIRCULATE-Japan GALAXY
AbstractPosterPoster PDF. An ASCO or ESMO member login may be required.
Level 2ESMO Congress 2024
Tomoya Harima · Abstract 555P · Poster · CIRCULATE-Japan GALAXY
AbstractPosterPoster PDF. An ASCO or ESMO member login may be required.
Level 2ESMO Congress 2024
Kozo Kataoka · Abstract 558P · Poster · CIRCULATE-Japan GALAXY
AbstractPosterPoster PDF. An ASCO or ESMO member login may be required.
Level 2prognosticASCO Annual Meeting 2023
Oki, Eiji · Abstract 3521 · GALAXY (CIRCULATE-Japan) · 2,083 analyzed of 3,615 enrolled; median follow-up 16.3 months
Signatera (tumor-informed)
286/2,083 (14%) were ctDNA-positive at the 4-week MRD timepoint and had inferior DFS (HR 12, 95% CI 9.1-15; P<0.0001). Versus patients who stayed negative (n=1,529), conversion from negative to positive (n=112) had HR 14.5 and persistent positivity (n=124) had HR 25.4. Median lead time from ctDNA to radiographic recurrence was 142 days among protocol-imaged recurrences.
AbstractFull paper
Level 1mixedESMO Congress 2023
Lonardi, S. · Abstract LBA28 · LBA · PEGASUS · 135 patients; median follow-up 20.8 months at this report
Guardant Reveal (v L1.2)
Post-surgery ctDNA was detected in 35/135 (26%). Relapse occurred in 12/35 (34%) ctDNA-positive vs 9/100 (9%) ctDNA-negative patients (HR 4.37, P=0.0003); the 9 negative relapses were the prespecified false-negative count. After 3 months of CAPOX, 11/35 positive patients converted to negative, but 8/11 later relapsed or re-positivized. Of 23 who received FOLFIRI after CAPOX, 11 converted and were relapse-free at analysis.
AbstractSlidesWebcastSlides + webcast. An ASCO or ESMO member login may be required.
Level 1positiveASCO Annual Meeting 2022
Tie, Jeanne · Abstract LBA100 · LBA · DYNAMIC · 455 randomized (302 ctDNA-guided, 153 standard management)
tumor-informed Safe-SeqS (named in the abstract)
Fewer patients in the ctDNA-guided arm received adjuvant chemotherapy (15.3% vs 27.9%; odds ratio 2.14; P=0.002). ctDNA-guided management was non-inferior for 2-year RFS (93.5% vs 92.4%; difference 1.1%, 95% CI -4.1% to 6.2%). After chemotherapy, 3-year RFS in ctDNA-positive patients was 86.4%; without chemotherapy, 3-year RFS in ctDNA-negative patients was 92.5% (96.7% in clinically low-risk disease).
AbstractFull paper
Level 2prognosticASCO Gastrointestinal Cancers Symposium 2022
Kotaka, Masahito · Abstract 9 · GALAXY (CIRCULATE-Japan) · 1,365 patients enrolled June 2020-April 2021 (this analysis); median follow-up 6.6 months
Signatera (tumor-informed)
6-month DFS by 4-to-12-week ctDNA dynamics: 98% if negative-to-negative (n=618), 100% if positive-to-negative (n=58), 59% if negative-to-positive (n=32), and 45% if positive-to-positive (n=78); HR 52.3 comparing conversion to clearance vs persistent positivity (P<0.001). Among 4-week MRD-positive patients, 12-week clearance was 57% (54/95) with adjuvant chemotherapy vs 8% (7/93) without (P<0.001). 6-month DFS in 4-week MRD-positive patients was 84% vs 34% with vs without ACT (HR 0.15, P<0.001).
AbstractFull paper
Level 3ESMO Congress 2022
Sae-Won Han · Abstract 381P · Poster
AbstractPosterPoster PDF. An ASCO or ESMO member login may be required.
Level 2ESMO Congress 2022
Daphne Day · Abstract 380P · Poster · ASCOLT
AbstractPosterPoster PDF. An ASCO or ESMO member login may be required.
Level 2positiveASCO Annual Meeting 2021
Sartore-Bianchi, Andrea · Abstract 3506 · CHRONOS · 52 screened by liquid biopsy; 36 (69%) negative for RAS/BRAF/EGFR mutations; 27 enrolled and treated
ctDNA genotyping for RAS/BRAF/EGFR mutations (assay brand not named in the extracted results)
The primary endpoint was met: partial response in 8/27 (ORR 30%, 95% CI 12-47%). Disease control (PR plus SD lasting more than 4 months) was 59%. Median PFS was 16 weeks. This is metastatic anti-EGFR rechallenge guided by ctDNA resistance mutations, not adjuvant MRD.
Abstract